With three assets in clinical and three in preclinical development (see Pipeline), Cartesian is the leader in RNA Cell Therapy. Our mission is to unleash the potential and reach of cell therapy through RNA engineering.
RNA Cell Therapy is a new class of therapy that blends some of the best features from conventional nanoparticle-based RNA therapy with conventional DNA-engineered cell therapy.
In contrast to conventional nanoparticle-based RNA therapies, RNA Cell therapy may have minimal immunogenicity with repeat dosing. It can also be easily engineered with tissue-specific homing proteins.
Compared to conventional DNA-based cell therapies, RNA Cell Therapy has a predictable half-life and avoids the risk of genomic integration: two attributes that are expected to make it safer. RNA Cell Therapy is also less expensive and enables true combination therapy without vector cargo limits.